Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP-EBMT.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
20
06
2020
accepted:
05
01
2021
revised:
14
12
2020
pubmed:
31
1
2021
medline:
27
7
2021
entrez:
30
1
2021
Statut:
ppublish
Résumé
We assessed the incidence and outcome of early candidemia after hematopoietic stem cell transplant (HSCT). The analysis included all first HSCTs performed from 2000 to 2015 in adult and pediatric patients with a non-leukemic disease and recorded in the EBMT registry. Overall survival (OS), non-relapse mortality (NRM), and relapse mortality (RM) were evaluated. Candidemia was diagnosed in 420 of 49,852 patients at a median time of 17 days post HSCT (range 0-100), the cumulative incidence being 0.85%. In 65.5% of episodes, candidemia occurred by day 30 after HSCT. The mortality rate by day 7 was 6.2%, whereas 100-day NRM was higher (HR 3.47, p < 0.0001), and 100-day OS was lower (HR 3.22, p < 0.0001) than that of patients without candidemia. After a median follow-up of 4.3 years, 5-year OS, NRM, and RM for patients with and without candidemia were 50.5% vs. 60.8%, p < 0.0001, 28.2% vs.18.8%, p < 0.0001, and 25.3% vs. 27.2%, p = 0.4, respectively. In conclusion, in non-leukemic transplant patients, the occurrence of an early episode of candidemia is rare but it is still associated with a negative effect on the outcome.
Identifiants
pubmed: 33514919
doi: 10.1038/s41409-021-01212-1
pii: 10.1038/s41409-021-01212-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1563-1572Références
Girmenia C, Raiola AM, Piciocchi A, Algarottii A, Stanzani M, Cudillo L, et al. Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014;20:872–80.
doi: 10.1016/j.bbmt.2014.03.004
Cesaro S, Tridello G, Castagnola E, Calore E, Carraro F, Mariotti I, et al. Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric onco-hematological patients. Eur J Haematol. 2017;99:240–8.
doi: 10.1111/ejh.12910
Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EG, Walsh TG, et al. Prospective surveillance for invasive fungal infections in hematopoietic stemcell transplant recipients, 2001–2006: overview of the Transplant-AssociatedInfection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091–1100.
doi: 10.1086/651263
Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV. Raad II, et al. Candidemia in patients with hematologic malignancies in the era of new antifungalagents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115:4745–52.
doi: 10.1002/cncr.24507
Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Allianee registry. Clin Infect Dis. 2009;48:265–73.
doi: 10.1086/595846
Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845–51.
doi: 10.1056/NEJM199203263261301
Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545–52.
doi: 10.1093/infdis/171.6.1545
Gamaletsou MN, Walsh TJ, Zaoutis T, Pagoni M, Kotsopoulou M, Voulgarelis M, et al. A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies. Clin Microbiol Infect. 2014;20:O50–7.
doi: 10.1111/1469-0691.12312
Cesaro S, Tridello G, Blijlevens N, Ljungman P, Craddock C, Michallet M, et al. Incidence, risk factors, and long-term outcome of acute leukemia patients with early candidemia after allogeneic stem cell transplantation: a study by the Acute Leukemia and Infectious Diseases Working Parties of European Society for Blood and Marrow Transplantation. Clin Infect Dis. 2018;67:564–72.
doi: 10.1093/cid/ciy150
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.
doi: 10.1086/588660
Maertens JA, Girmenia C, Brüggemann RJ, Duarte RF, Kibbler CC, Ljungman P, et al. European guidelines for primary antifungal prophylaxis in adult haematologypatients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73:3221–30.
pubmed: 30085172
Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T. The EBMT handbook, 5th edition, hematopoietic stem cell transplantation. Genova, Italy: EBMT and ESH. Forum Service Editore; 2008.
Bearman SI, Appelbaum FR, Back A, Petersen FB, Buckner CD, Sullivan KM, et al. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol. 1989;7:1288–94.
doi: 10.1200/JCO.1989.7.9.1288
Sullivan KM. Acute and chronic graft-versus-host disease in man. Int J Cell Cloning. 1986;4:42–93.
doi: 10.1002/stem.5530040710
Averbuch D, Tridello G, Hoek J, Mikulska M, Akan H, Yanez San Segundo L. et al. Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clin Infect Dis. 2017;65:1819–28.
doi: 10.1093/cid/cix646
Girmenia C, Bertaina A, Piciocchi A, Perruccio K, Algarotti A, Busca A, et al. Incidence, risk factors and outcome of pre-engraftment Gram-negative bacteremia after allogeneic and autologous hematopoietic stem cell transplantation: an Italian Prospective Multicenter Survey. Clin Infect Dis. 2017;65:1884–96.
doi: 10.1093/cid/cix690
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44.
doi: 10.1056/NEJMoa1706640
Penack O, Tridello G, Hoek J, Socié G, Blaise D, Passweg J, et al. Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: aretrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties. Bone Marrow Transplant. 2016;51:418–23.
doi: 10.1038/bmt.2015.237
Styczynski J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant. 2020;55:126–36.
doi: 10.1038/s41409-019-0624-z
Pagano L, Caira M, Nosari A, Van Lint MT, Candoni A, Offidani M, et al. Fungal infections in recipients of hematopoietic stem cell transplants: resultsof the SEIFEM B-2004 study–Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis. 2007;45:1161–70.
doi: 10.1086/522189
Criscuolo M, Marchesi F, Candoni A, Cattaneo C, Nosari A, Veggia B, et al. Fungaemia in haematological malignancies: SEIFEM-2015 survey. Eur J Clin Invest. 2019;49:e13083.
doi: 10.1111/eci.13083
Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48:265–73.
doi: 10.1086/595846
Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48:1695–703.
doi: 10.1086/599039
Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag. 2014;10:95–105.
doi: 10.2147/TCRM.S40160
Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis. 2000;181:309–16.
doi: 10.1086/315193
Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem celltransplantation (HCT). Clin Microbiol Infect. 2012;18 S:53–67.
doi: 10.1111/1469-0691.12041
Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W, et al. Guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15:e327–40.
doi: 10.1016/S1470-2045(14)70017-8
Cornely OA, Gachot B, Akan H, Bassetti M, Uzun O, Kibbler C, et al. Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). Clin Infect Dis. 2015;61:324–31.
doi: 10.1093/cid/civ293
Patil A, Majumdar S. Echinocandins in antifungal pharmacotherapy. J Pharm Pharmacol. 2017;69:1635–60.
doi: 10.1111/jphp.12780
Pagano L, Dragonetti G, Cattaneo C, Marchesi F, Veggia B, Busca A, et al. Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report. Haematologica. 2017;102:e407–10.
doi: 10.3324/haematol.2017.172536